Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide

EJHaem. 2023 Aug 25;4(4):1212-1215. doi: 10.1002/jha2.767. eCollection 2023 Nov.

Ing S Tiong^{1

2

3}, William S Stevenson^{4

5}, Meaghan Wall^{3

6}, Yan Zhuang Yap¹, John F Seymour^{1

7

8}, Melita Kenealy^{3

9}, Piers Blombery^{1

7

8}; Australasian Leukaemia & Lymphoma Group

¹ Peter MacCallum Cancer Centre Melbourne Victoria Australia.
² The Alfred Hospital Melbourne Victoria Australia.
³ Monash University Melbourne Victoria Australia.
⁴ Royal North Shore Hospital St Leonards New South Wales Australia.
⁵ Northern Clinical School, University of Sydney Sydney New South Wales Australia.
⁶ Victorian Clinical Genetics Services, Murdoch Children's Research Institute Melbourne Victoria Australia.
⁷ Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Victoria Australia.
⁸ Royal Melbourne Hospital Melbourne Victoria Australia.
⁹ Cabrini Health Melbourne Victoria Australia.

No abstract available